NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline<
28 Sep 2020

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

Ysios Capital joins Galecto 66M USD financing round.
24 Sep 2020

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

Sperogenix Therapeutics and Minoryx Therapeutics announce that they have entered into an exclusive license agreement for the development and commercialization of leriglitazone.
LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs<
18 Sep 2020

LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs

Ysios Capital joins LAVA Therapeutics 83MUSD financing
ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio<
15 Sep 2020

ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio

ProteoDesign rebrands as Splice Bio to develop novel gene therapies based on its proprietary intein technology.
15 Sep 2020

Galecto’s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase 1 Clinical Data Presented Recently at Several Scientific Conferences

Galecto, Inc. today announced it has received Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Medicines Agency for GB0139 in the treatment of Idiopathic Pulmonary Fibrosis.
Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma<
11 Sep 2020

Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma

AU-011 Continues to Demonstrate a Favorable Safety Profile Along with Promising Tumor Control and Vision Preservation.
09 Sep 2020

Medlumics raises €14M in a Series E financing co-led by Asabys Partners, VI Partners and CDTI Innvierte, together with existing investors Andera Partners, Caixa Capital Risc and Innogest

Medlumics announces today the closing of a €14 million Series E financing, co-led by Asabys Partners, VI Partners and CDTI Innvierte, with the participation from historical investors Andera Partners, Caixa Capital Risc and Innogest Capital.
27 Aug 2020

Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary Fibrosis

Galecto, Inc. today announced it has received Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Medicines Agency for GB0139 in the treatment of Idiopathic Pulmonary Fibrosis (IPF).
20 Aug 2020

Sanifit Appoints Adam Levy as Chief Financial Officer

Sanifit today announced the appointment of Adam Levy as Chief Financial Officer, with immediate effect.
21 Jul 2020

CorWave Awarded €2.5M From the European Commission Through the EIC Accelerator Program

CorWave will receive a €2.5 million grant from the European Innovation Council (EIC) to develop its innovative Left Ventricular Assist Device (LVAD).

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.